Brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to post sales of $5.79 million for the current quarter, according to Zacks. Four analysts have issued estimates for ADMA Biologics’ earnings. The lowest sales estimate is $5.00 million and the highest is $6.30 million. ADMA Biologics posted sales of $12.00 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 51.8%. The company is scheduled to issue its next earnings report on Monday, March 4th.

According to Zacks, analysts expect that ADMA Biologics will report full-year sales of $19.60 million for the current financial year, with estimates ranging from $18.00 million to $21.00 million. For the next fiscal year, analysts expect that the firm will post sales of $50.66 million, with estimates ranging from $27.00 million to $111.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The company had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $5.39 million.

A number of analysts recently issued reports on ADMA shares. Oppenheimer set a $13.00 price objective on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Wednesday, September 5th. HC Wainwright started coverage on shares of ADMA Biologics in a report on Tuesday, October 30th. They set a “buy” rating and a $17.00 price objective for the company. Maxim Group raised their price objective on shares of ADMA Biologics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, July 26th. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Finally, Raymond James restated a “buy” rating and set a $10.00 price objective (down previously from $11.00) on shares of ADMA Biologics in a report on Friday, October 12th. Eight analysts have rated the stock with a buy rating, ADMA Biologics currently has an average rating of “Buy” and a consensus price target of $11.58.

NASDAQ ADMA traded down $0.48 during trading hours on Friday, reaching $5.26. 177,456 shares of the company were exchanged, compared to its average volume of 226,392. ADMA Biologics has a 1 year low of $2.10 and a 1 year high of $6.96. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65. The company has a market capitalization of $266.97 million, a PE ratio of -2.75 and a beta of 2.28.

Large investors have recently modified their holdings of the business. AMP Capital Investors Ltd bought a new position in ADMA Biologics during the second quarter worth about $109,000. Renaissance Technologies LLC bought a new position in ADMA Biologics during the second quarter worth about $132,000. Schwab Charles Investment Management Inc. bought a new position in ADMA Biologics during the second quarter worth about $160,000. Spark Investment Management LLC boosted its position in ADMA Biologics by 68.7% during the second quarter. Spark Investment Management LLC now owns 37,460 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 15,260 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in ADMA Biologics during the first quarter worth about $182,000. Hedge funds and other institutional investors own 55.07% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: Float

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.